Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Completed · Phase 1
Conditions studied: Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
In brief
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic cancer. In this study, the safety and tolerability of CLT-008 administered 24 hours after an umbilical cord blood transplant will be determined by monitoring for adverse reactions, neutrophil and platelet recovery, hematopoietic chimerism, graft-versus-host disease (GVHD), and infections.
Key facts
- Study ID
- NCT00891137
- Run by
- Cellerant Therapeutics
- People needed
- 30
- Starts
- 2009-04-01
- Expected to finish
- 2014-06-01
- Last updated by the study team
- 2014-10-27
Who can join
Age: 12 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Children's Hospital of Orange County — Orange, California, United States
- Alfred I. duPont Hospital for Children — Wilmington, Delaware, United States
- Children's National Medical Center — Washington D.C., District of Columbia, United States
- Loyola University Medical Center, Cardinal Bernardin Cancer Center — Maywood, Illinois, United States
- University of Minnesota: Masonic Cancer Center, BMT Clinic, and Fairview Medical Center — Minneapolis, Minnesota, United States
- Cleveland Clinic, Taussig Cancer Institute — Cleveland, Ohio, United States
- Nationwide Children's Hospital — Columbus, Ohio, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.